Ultragenyx Pharmaceutical RARE Balance Sheet Statement
| TTM Q1 '26 | TTM Q4 '25 | TTM Q3 '25 | TTM Q2 '25 | TTM Q1 '25 | ||
|---|---|---|---|---|---|---|
| $175M+37.8% | $421M+142% | $202.51M+34.5% | $176.31M-63.3% | $127M+13.1% | ||
| $238M-35.2% | $259M-40.6% | $222.74M-52.7% | $311.28M+9.9% | $367.39M+22.5% | ||
| $121M+22.4% | $158M+29.5% | $112.54M+20.6% | $124.46M+17.4% | $98.84M-1.4% | ||
| $55M+19.5% | $52M+15.6% | $52.2M+20.5% | $46.5M+15.8% | $46.03M+28.2% | ||
| $657M-6.0% | $951M+16.4% | $643.21M-19.6% | $719.79M-25.4% | $699.16M+17.3% | ||
| $239M-8.4% | $244M-8.3% | $249.96M-8.3% | $255.76M-8.2% | $260.91M-8.5% | ||
| $44M-0.9% | $44M0.0% | $44.41M0.0% | $44.41M0.0% | $44.41M0.0% | ||
| $174M-1.4% | $176M-1.1% | $172.94M+4.9% | $174.73M+5.1% | $176.52M+7.0% | ||
| $30M-0.2% | $30M0.0% | $30.06M0.0% | $30.06M0.0% | $30.06M0.0% | ||
| $61M-2.2% | $60M-4.8% | $57.86M+7.4% | $60.12M+11.8% | $62.37M+4.0% | ||
| $121M+76.5% | $57M-57.8% | $22.07M-89.1% | $51.45M-53.5% | $68.56M-56.2% | ||
| $1.3B-1.2% | $1.53B+1.9% | $1.19B-22.6% | $1.31B-19.3% | $1.31B+0.4% | ||
| $17M+408% | $19M+375% | $1.24M-74.4% | $2.58M-98.3% | $3.35M-97.8% | ||
| $325M+11.4% | $384M+11.6% | $340.02M+19.3% | $293.24M+7.5% | $291.67M+18.8% | ||
| $42M+145% | $44M+159% | $18.78M+16.5% | $17.4M+14.5% | $17.12M+18.3% | ||
| $1.53B+31.4% | $1.61B+29.3% | $1.17B-0.9% | $1.15B-3.2% | $1.16B-0.5% | ||
| $0— | $0— | $0— | $0— | $0— | ||
| $0-100% | $0— | $96K+4.3% | $96K+4.3% | $94K+13.3% | ||
| $4.48B+5.4% | $4.45B+5.6% | $4.41B+5.8% | $4.37B+6.1% | $4.25B+15.0% | ||
| -$4.72B-14.8% | -$4.53B-14.5% | -$4.4B-15.2% | -$4.22B-14.4% | -$4.11B-15.4% | ||
| $0+100% | $1M+200% | $820K-8.5% | -$268K+75.5% | -$341K+20.9% | ||
| $10M+32.2% | $8M+100% | $7.99M+125% | $7.99M+135% | $7.57M+127% | ||
| -$236M-264% | -$80M-131% | $9.16M-97.4% | $151.29M-65.0% | $144M+2.7% | ||
| $1.3B-1.2% | $1.53B+1.9% | $1.19B-22.6% | $1.31B-19.3% | $1.31B+0.4% | ||
| $238M-35.2% | $259M-40.6% | $222.74M-52.7% | $311.28M+9.9% | $367.39M+22.5% | ||
| $61M-2.2% | $60M-4.8% | $57.86M+7.4% | $60.12M+11.8% | $62.37M+4.0% | ||
| $121M+76.5% | $57M-57.8% | $22.07M-89.1% | $51.45M-53.5% | $68.56M-56.2% | ||
| $174M-1.4% | $176M-1.1% | $172.94M+4.9% | $174.73M+5.1% | $176.52M+7.0% | ||
| $61M-2.2% | $60M-4.8% | $57.86M+7.4% | $60.12M+11.8% | $62.37M+4.0% | ||
| $61M-2.2% | $60M-4.8% | $57.86M+7.4% | $60.12M+11.8% | $62.37M+4.0% | ||
| $194M+12.1% | $265M+10.0% | $220.53M+19.2% | $180.79M+17.1% | $173.01M+16.0% | ||
| $194M+12.1% | $265M+10.0% | $220.53M+19.2% | $180.79M+17.1% | $173.01M+16.0% | ||
| $72M+25.5% | $69M+38.0% | $65.55M+34.5% | $63.86M+36.1% | $57.38M+34.4% | ||
| $17M— | $19M— | $1.24M— | $2.58M— | —— | ||
| $0-100% | $0— | $96K+4.3% | $96K+4.3% | $94K+13.3% | ||
| $0— | $0— | $0— | $0— | $0— | ||
| $10M+32.2% | $8M+100% | $7.99M+125% | $7.99M+135% | $7.57M+127% | ||
| $30M-0.2% | $30M0.0% | $30.06M0.0% | $30.06M0.0% | $30.06M0.0% | ||
| $1.13B+42.1% | $1.15B+39.9% | $763.74M-7.9% | $782.75M-7.1% | $794.05M-6.4% | ||
| $10M+32.2% | $8M+100% | $7.99M+125% | $7.99M+135% | $7.57M+127% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- Can Ultragenyx Pharmaceutical cover its short-term obligations?
- Its current ratio is 2.02 — current assets exceed current liabilities.
- Where does Ultragenyx Pharmaceutical's balance sheet data come from?
- Every line is extracted from Ultragenyx Pharmaceutical's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.